Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 3/20 | 0.65 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMO | O15229 | 2/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15947898 | 0.85 | PIM1 (0.57) | PIM1MAP4K4KMOHRH4PLK1 | |
| SCHEMBL4106824 | 0.84 | ASIC3 (0.50) | ASIC3CAMK2DPIM1MAP4K4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL15659071 | 0.83 | PIM1 (0.55) | PIM1MAP4K4KMOHRH4PLK1 | |
| SCHEMBL2362701 | 0.80 | ABCG2 (0.44) | ASIC3CAMK2DMAP4K4KMOHRH4 | |
| SCHEMBL3788626 | 0.79 | ASIC3 (1.00) | ASIC3ALDH1A1 | |
| SCHEMBL29282119 | 0.79 | KMO (0.53) | PIM1MAP4K4KMOPLK1KDM1A | |
| SCHEMBL30913194 | 0.79 | KMO (0.53) | PIM1MAP4K4KMOPLK1KDM1A | |
| SCHEMBL1091767 | 0.79 | CYP2A6 (0.57) | PIM1KMOPLK1NUDT1CYP19A1 | |
| SCHEMBL30337333 | 0.76 | ASIC3 (0.79) | ASIC3MAP4K4ALDH1A1KMO | |
| SCHEMBL23259181 | 0.76 | ASIC3 (0.66) | ASIC3MAP4K4KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073918-B2 | Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-05 | — | — | US | disclosed |
| WO-2011146287-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | ALK, ALKBH5, ALKBH3 | ASIC3 1070/4885CAMK2D 2412/4885PIM1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.